FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality^® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults. 

Full story.